Want to see RXRX full AI Analyst Report?
Revenue by Segment
Breaks down revenue by different business units or product lines, highlighting which areas are driving growth and which may need strategic adjustments. This insight helps assess the company's diversification and dependency on specific segments.Recursion’s revenue mix is lumpy and milestone‑driven — operating revenue spikes align with partner inflows rather than repeat commercial sales, while grants are immaterial and erratic; management’s >$500M of partner payments and 10 delivered milestones explain the quarter‑to‑quarter surges. That means near‑term topline strength and the stated runway depend on timing of partner milestones and program opt‑ins, not product revenue; cost cuts help, but delays in clinical readouts or milestones would quickly pressure financing — upcoming opt‑ins/registrational decisions are the key revenue catalysts.
Date | Grant | Operating |
|---|---|---|
Jun 30, 2026 | $367.00K | $7.30M |
Mar 31, 2026 | $171.00K | $6.30M |
Dec 31, 2025 | $186.00K | $35.35M |
Sep 30, 2025 | $192.00K | $4.98M |
Jun 30, 2025 | $120.00K | $19.10M |
Mar 31, 2025 | -$73.00K | $14.82M |
Dec 31, 2024 | $35.00K | $4.51M |
Sep 30, 2024 | $0.00 | $26.08M |
Jun 30, 2024 | $13.00K | $14.40M |
Mar 31, 2024 | $303.00K | $13.49M |